CTOs on the Move

Shape Therapeutics

www.shapetx.com

 
Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.shapetx.com
  • 500 Yale Ave N 3rd floor
    Seattle, WA USA 98109
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Shape Therapeutics raised $35.5M on 11/06/2019

Similar Companies

Mcnan Technologies Inc

Mcnan Technologies Inc is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artiva Biotherapeutics

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

InVitria

InVitria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cedilla Therapeutics

We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.

Orig3n

Founded in 2014, Boston based Orig3n exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we`re on a mission to accelerate the future of regenerative medicine.